Clinical Genomics, a leading provider of cancer testing solutions and liquid biopsy testing, has announced the appointment of two new directors to its board.
Mary Padbury is the new Chairman and Katherine Bach Kalin is a director.
Ms Padbury has extensive international, legal, and governance experience, including as an adviser on intellectual property to Australian and multinational companies
Ms Kalin joins the board with over 25 years of experience as a senior executive in the healthcare and professional services industries, with multi-disciplinary expertise across diagnostics, medical devices, and pharmaceuticals.
“We are pleased to welcome Mary as incoming Chair of our Board of Directors. She brings to our company a deep understanding of how to effectively commercialize new healthcare technologies,” said Dr Lawrence LaPointe, CEO of Clinical Genomics.
“Mary will be a vital asset to our Board and will provide valuable leadership to the organization. I would also like to thank Max Mawhinney for his many years of service as Chairman of Clinical Genomics. We look forward to his continued guidance and leadership as a member of our Board of Directors. We are also extremely fortunate to have Katherine, with her extensive global experience and expertise in the healthcare industry, as a member of our Board as we continue to carry out our mission.”
“I am excited to join Clinical Genomics and do my part to help the company achieve its mission of harnessing breakthrough science to create innovative healthcare products that improve patient outcomes by detecting cancer earlier,” said Ms Kalin.
“I have tremendous respect for my fellow Board members and the Clinical Genomics management team, and I look forward to working with them,” added Ms Padbury.
Prior to retiring and joining Clinical Genomics, Ms Padbury was a partner and vice chairman of Ashurst, a global commercial law firm, and served as chairman of Ashurst Australia for eight years before the firm’s full merger with Ashurst LLP in 2013.
She currently serves as chairman of the Board for Trans-Tasman IP Attorneys and is a member of the Board for the Macfarlane Burnet Institute for Medical Research and Public Health Ltd., Commonwealth Bank of Australia, and Victorian Legal Admissions Committee.
Prior to joining Clinical Genomics, Ms Kalin led corporate strategy at Celgene, a global biopharmaceutical company, for five years.
She held leadership roles in marketing, sales, strategy and new business development at Johnson & Johnson during the period from 2002 to 2011.